Articles Vol. 65 No. CĐ10 - Bệnh viện Thống Nhất 30/10/2024

6. EVALUATION OF AFATINIB EFFICACY AS FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH EGFR MUTATIONS AT THONG NHAT HOSPITAL

Nguyen Dac Nhan Tam1,2, Truong Hoang Kim3,4, Nguyen Thi Dai Hong1,2, Pham Thanh Hang1,2
1 Thong Nhat Hospital
2 Bệnh viện Thống Nhất
3 University of Health Sciences - Vietnam National University at Ho Chi Minh City
4 Trường Đại học Khoa học Sức khỏe - Đại học Quốc gia Thành phố Hồ Chí Minh
Corresponding author: phd2051001@studenthuph.edu.vn
DOI: 10.52163/yhc.v65iCD10.1589
17 Views
16 Downloads
Keywords
Advanced stage non-small cell lung cancer EGFR gene mutation afatinib
Abstract

Advanced non-small cell lung cancer (NSCLC) with EGFR (Epidermal Growth Factor Receptor) mutations shows high efficacy with EGFR TKIs (Tyrosine Kinase Inhibitors) in terms of progression-free survival (PFS) and disease control rate (DCR) compared to standard chemotherapy.

Objective: To evaluate the response rate of afatinib in first-line treatment for advanced NSCLC (stage IIIC, IV) with EGFR mutations and its adverse effects.

Methods: A retrospective descriptive study of 16 patients with advanced non-small cell lung cancer with EGFR mutations treated with afatinib as first-line therapy at Thong Nhat Hospital from January 1, 2018 to July 31, 2022.

Results: The average age was 66 years (66.06 ± 12.81), with the oldest patient being 88 years old and the youngest being 45 years old. Female patients accounted for a higher percentage compared to male patients, with rates of 75% and 25%, respectively. The complete response (CR) rate was 12.5%, partial response (PR) was 50%, stable disease (SD) was 31.3%, and progressive disease (PD) was 6.3%. The disease control rate (DCR) was 93.8%, with a median PFS of 23 months and a median overall survival (OS) of 38 months. Common adverse effects included rash (100%), diarrhea (93.8%), paronychia (87.5%), and stomatitis (87.5%). No grade 3 or 4 adverse effects were observed.

Conclusion: Afatinib provides a high response rate in patients with advanced non-small cell lung cancer with EGFR mutations sensitive to TKIs. Adverse effects can be controlled.

References
[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660. Google Scholar
[2]
Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May. 143 (5 Suppl): e142S-e165S.). Google Scholar
[3]
Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947- 957. Google Scholar
[4]
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small- cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13: 239-246. Google Scholar
[5]
Wu YL, Cheng Y, Zhou X, et al Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation- positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18:1454-1466. Google Scholar
[6]
Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUXLung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15: 213-222. Google Scholar
[7]
Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31: 3327-3334. Google Scholar
[8]
Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first -line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, openlabel, randomised controlled trial. Lancet Oncol. 2016; 17: 577-589. Google Scholar
[9]
Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUXLung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015; 16: 141-151. Google Scholar
[10]
Watanabe S, Minegishi Y, Yoshizawa H, et al. Effectiveness of gefitinib against non- small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol. 2014; 9: 189-194. Google Scholar
[11]
Yang J et al. J Clin Oncol 33, 2015 (suppl; abstr 8073); Schuler M et al., ELCC 2016, #138PD; Hirsh V JCO 34, 2016 (suppl; abstr 9046). Google Scholar
[12]
Keunchil Park, Darren Wan-Teck Lim, and James Chih-Hsin Yang J Clin Oncol 36, 2018. First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting. Abstract nr e21060. Google Scholar
[13]
Halmos et all with Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo), Lung Cancer 2019. Google Scholar